Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

Celgene is without a doubt interested in buying Prurisol and maybe all of Innovation Pharmaceuticals

As you know Celgene has a market capitalization of over $100 Billion.

You may or may not know that virtually all of Celgene's blockbuster drugs are derivatives of thalidomide and are used mainly for treating cancers such as multiple myeloma.

https://en.wikipedia.org/wiki/Development_of_analogs_of_thalidomide

Even Celgene's Otetzla (apremilast) is a derivative of thalidomide.

Thalidomide and it's derivatives work as angiogenesis inhibitors. mainly they inhibit angiogenesis by inhibiting VEGF, bFGF and other vascular growth factors. Psoriasis is at least partly caused by aberrant angiogenesis.

Since Prurisol is a potent inhibitor of IL-20, Prurisol most probably inhibits angiogenesis by inhibiting VEGF, bFGF and other vascular growth factors.

Quote:
"...Serum levels of IL-20 correlated positively with levels of angiogenic cytokines and bone marrow MVD (p < 0.01 for MVD, p < 0.002 for VEGF and p < 0.001 for the other cases). Our results strongly suggest that serum IL-20 concentrations participate actively in the pathophysiology of MM progression...."


By inhibiting IL-20 you can inhibit microvasclular density MVD, VEGF and othe vascular growth factors.

Prurisol could be an oral equivalent of Novartis' and Roche's Avastin and Lucentis and better than Celgene's Revlimid, Pomalyst, Thalomid.

Prurisol and its derivatives could be a family of oral angiogenesis inhibitors that would allow Innovation Pharmaceuticals to have a market capitalization of more than $100 Billion in the next decade.

Compete head on head against or partner with Celgene.

Angiogenesis and Inflammation are very much related.

************************************************************************
Circulating serum levels of IL-20 in multiple myeloma patients: its significance in angiogenesis and disease activity.
Alexandrakis MG1, Pappa CA, Kokonozaki M, Boula A, Vyzoukaki R, Staphylaki D, Papadopoulou A, Androulakis N, Tsirakis G, Sfiridaki A.
Author information
1
Dept of Heamatology, University Hospital of Heraklion, PO Box 1352, 71110, Heraklion, Greece, [e-mail].
Abstract
Angiogenesis is an important hallmark in multiple myeloma (MM) pathogenesis, with the participation of various versatile molecules. Interleukin-20 (IL-20) is a pro-inflammatory cytokine with diverse angiogenic properties. Our purpose was to estimate the possible impact of IL-20 on MM angiogenesis and disease activity. We measured serum levels of IL-20 along with levels of vascular endothelial growth factor (VEGF), basic-fibroblast growth factor and angiopoietin 2 in 58 active MM myeloma patients, in 32 of them who responded to bortezomib-based therapy and in 20 controls. We also measured bone marrow microvasclular density (MVD) by immunohistochemical method. Serum levels of all cytokines and bone marrow MVD were higher in active MM patients compared to controls and responders to bortezomib-based therapy (p < 0.001 in all cases). They were also in parallel with International Staging System stages (p < 0.001 for all cases). Serum levels of IL-20 correlated positively with levels of angiogenic cytokines and bone marrow MVD (p < 0.01 for MVD, p < 0.002 for VEGF and p < 0.001 for the other cases). Our results strongly suggest that serum IL-20 concentrations participate actively in the pathophysiology of MM progression. Therefore, it could be used as an indicator of the disease progression and angiogenesis processes.

https://www.ncbi.nlm.nih.gov/pubmed/25631632

Good luck and GOD bless,

George